1 15 November 2018 2 EMA/CHMP/BPWP/144552/2009 rev. 2 Corr. 1 3 Committee for medicinal products for human use (CHMP) 4 Guideline on clinical investigation of recombinant and 5 human plasma-derived factor IX products 6 Draft Draft Agreed by Blood Products Working Party (BPWP) August 2018 Adopted by Committee for Medicinal Products for Human Use (CHMP) 15 November 2018 Start of public consultation 3 December 2018 End of public consultation 30 June 2019 7 8 This guideline replaces ‘Guideline on clinical investigation of recombinant and human plasma-derived 9 factor IX products’ (EMA/CHMP/BPWP/144552/2009 Rev. 1, Corr. 1) 10 Comments should be provided using this template. The completed comments form should be sent to
[email protected] 11 Keywords Recombinant factor IX, plasma-derived factor IX, efficacy, safety, immunogenicity, inhibitor, thrombogenicity, anaphylactic reactions, potency assays 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 12 Guideline on the clinical investigation of recombinant and 13 human plasma-derived factor IX products 14 Table of contents 15 Executive summary ..................................................................................... 4 16 1. Introduction (background) .....................................................................